ADAS-Cogparkinson s diseaseMRIdementiaclinical neurologyBackground The ADAS-Cog is a principal outcome measure for clinical trials of Alzheimer's disease (AD). To date decisions on how much change in ADAS-Cog score is clinically relevant has been based on consensus opinion. We aimed to use ...
Patients randomized to cholinesterase inhibitors improved 1.7 points on the 120-point NPI scale compared with placebo (95% confidence interval [CI], 0.87-2.57); there was no significant difference between the groups when theADAS-noncogscale was used as the outcome measure. ...
The companies said that Dimebon did not achieve statistically significant results for either of the two co-primary endpoints, the Alzheimer's Disease Assessment Scale, which is the cognitive subscale (ADAS-cog) which measures cognitive ability, or the Alzheimer's Disease Cooperative Study, the Activi...
Objective To establish the minimal clinically relevant change (MCRC) on the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) for patients with mild Alzheimer's disease (AD).AnetteDepartmentSchragDepartmentJonathanDepartmentMDepartmentSchott...
The Disability Assessment for Dementia (DAD) scale was also used as a measure of dependence. Disability was predicted directly using MMSE and ADAS-cog and compared to predictions from converted scores./p pResults/p pThe odds ratio of dependence was significantly higher amongst the patients with ...
A retrospective analysis using data-monitoring algorithms: What are the logical relationships between the ADAS-Cog and mmse?Yavorsky, CDiClemente, GOpler, MJovic, SRothman, BDeFries, A
This endpoint was measured by the ADAS-Cog scale and Clinical Global Impression of Change (CGIC) scale at regular intervals up to 1 year after the study’s beginning. Also, the adverse effects reported by patients were examined. Although this trial was completed in June 2011, results are not...
This endpoint was measured by the ADAS-Cog scale and Clinical Global Impression of Change (CGIC) scale at regular intervals up to 1 year after the study’s beginning. Also, the adverse effects reported by patients were examined. Although this trial was completed in June 2011, results are not...
9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook AcronymDefinition ADNIAlzheimer's Disease Neuroimaging Initiative ADNIAssociate Director of National Intelligence ADNIAsia Defence News International(publisher; India) ...